Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
55
resultados
Última actualización
15/06/2025 [07:36:00]
Resumen de: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Resumen de: US2025189543A1
A method for quantifying active orexin A in a specimen, comprising: a step of contacting the specimen with a monoclonal antibody that recognizes the C-terminal side of orexin A to separate orexin A species; a step of digesting the separated orexin A species with a protease to obtain a peptide consisting of an amino acid sequence of SEQ ID NO: 1; and a step of performing mass spectrometry on the peptide.
Resumen de: US2025189536A1
The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.
Resumen de: US2025189517A1
A solution is described for preserving cells and/or extra cellular components in naturally expressed bodily fluids (e.g. saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition. The solution may be hypertonic with respect to blood. Techniques are described for enriching cells from a sample of a naturally expressed bodily fluid, and/or for analysis, e.g. to diagnose medical conditions such as cancer, obesity, infections, autism, Alzheimer disease, hetotological disorders, cardiovascular disease or disorders, diabetes, vulnerable plack, LTBI, HIV infection, COPD, ACQS.
Resumen de: US2025191903A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: EP4567427A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: AU2023356443A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Resumen de: US2022373562A1
The present disclosure relates generally to a sensor chip and methods for the detection of an analyte. In particular, the disclosure relates to a sensor chip for detecting an analyte in a subject suffering from a neurodegenerative disease. The sensor chip comprises a conductive layer on a membrane support layer, wherein a plurality of apertures extend through the conductive layer and the membrane support layer and are arranged such that illumination of the conductive layer and/or the membrane support layer produces a surface plasmon resonance.
Resumen de: US2025179489A1
An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: WO2024026413A2
Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: AU2023334129A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Resumen de: US2025060376A1
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025172555A1
The present invention relates to a lateral flow test device capable of detecting the presence or absence of unfolded p53 in a liquid sample, such as a blood sample. Also provided are methods of using such a device for quantitative or qualitative measurement of U-p53 in a liquid sample. Detection of the presence of this analyte in the sample identifies if the subject has a risk to develop Alzheimer's Disease, and also is useful to confirm a diagnosis of Alzheimer's disease.
Resumen de: US2025170124A1
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
Resumen de: US2025172549A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: US2024141033A1
The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: WO2025102250A1
A method, system, composition and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on human brain hippocampus spatial transcriptomics. The present invention achieves rapid and efficient early diagnosis and differential diagnosis of AD cognitive disorder by means of one or more of CCK, Neurogranin and PMP2 carried in plasma extracellular vesicles (EVs), thereby achieving high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, having the advantages of rapidness and low cost, and providing a new technical means and method for clinical application of AD cognitive disorder and large-scale screening-related accurate diagnosis work.
Resumen de: US2025163135A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: US2025164471A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Nº publicación: US2025163372A1 22/05/2025
Solicitante:
CASSAVA SCIENCES INC [US]
Cassava Sciences, Inc
Resumen de: US2025163372A1
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
BOPI
Sede Electrónica
